ComplyRx
Built by ComplyRx

Compare clinical trial pipelines, export for presentations

sacituzumab govitecan (16) vs trastuzumab deruxtecan (16)30 active2016–2034
sacituzumab govitecantrastuzumab deruxtecan
Key
Actual date
Anticipated
Forecast to primary completion
RecruitingActive, not recruitingNot yet recruitingCompleted
'16
'18
'20
'22
'24
'26
'28
'30
'32
'34
sacituzumab govitecan
TROPiCS-03P2
SASCIAP3
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)P3
Scalp Cooling in MBCP2
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)P2
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)P3
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)P2
Circulating Tumor DNA to Guide Changes in Standard of Care ChemotherapyP2
ASCENT-GYN-01P3
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionP2
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBCP2
OASISP2
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerP3
ADAPT-TN-IVP3
PROBEP2
trastuzumab deruxtecan
TAPURP2
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]P2
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]P3
DG-03P2
DPT01P2
Scalp Cooling in MBCP2
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsP3
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)P2
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsP2
DESTINY-BTC01P3
TRADE DXdP2
Perioperative Therapies in Locally Advanced Unresectable Gastric CancerP2
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerP3
Optimal Application Timing of ADC Drugs for Advanced Breast CancerP2
ASPEN-09-03P2
A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast CancerP2

Upcoming readouts

24 ahead · 2 drugs

Select a trial to load its full ClinicalTrials.gov record.

Trial Pipeline · How it works

Search, compare, export.

Three steps from drug name to a presentation-ready pipeline view, with live trial data, side by side.

  1. 01 · SEARCH

    Search drugs

    Type a drug name and see the phase 2-4 trials from ClinicalTrials.gov.

  2. 02 · COMPARE

    Compare timelines

    See start dates, primary completions, and status on one timeline, up to five drugs at once.

  3. 03 · EXPORT

    Export for your deck

    Download a branded PNG or PDF. Share the URL. Every comparison state is linkable.

FAQ

Where does the data come from?
All trial data is sourced from ClinicalTrials.gov (CTGov). Results are cached for up to 6 hours so repeat loads stay fast.
Is this free?
Yes. Compare up to five drugs and export PNG or PDF at no cost. Export requires a one-time email to join the ComplyRx waitlist.
What is ComplyRx?
ComplyRx is an all-in-one marketing/competitive intelligence platform for organisations and individuals that work in healthcare, life sciences, and the pharmaceutical industry.

Keep following
what matters.

Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

Build your watch

Choose what to track in the watch builder.